ABC Arbitrage SA Invests $260,000 in Evotec AG (NASDAQ:EVO)

Key Points

• ABC Arbitrage SA acquired 77,919 shares of Evotec AG, valued at around $260,000, according to their recent Form 13F filing with the SEC.
• Institutional investors have shown significant interest in Evotec, with DCF Advisers LLC increasing its stake by 227% and Bank of America boosting its stake by 262.5% in recent quarters.
• Evotec's stock has seen price fluctuations, with a 1-year low of $2.84 and a high of $5.64, while several analysts have upgraded their ratings on the company recently.

ABC Arbitrage SA purchased a new stake in Evotec AG (NASDAQ:EVO - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 77,919 shares of the company's stock, valued at approximately $260,000.

Several other hedge funds have also made changes to their positions in the company. BNP Paribas Financial Markets acquired a new stake in Evotec in the 4th quarter valued at approximately $27,000. CSS LLC IL acquired a new stake in Evotec in the 4th quarter valued at approximately $50,000. Bank of America Corp DE increased its holdings in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after purchasing an additional 9,289 shares during the last quarter. Lighthouse Investment Partners LLC acquired a new stake in Evotec in the 4th quarter valued at approximately $166,000. Finally, DCF Advisers LLC increased its holdings in Evotec by 227.0% in the 1st quarter. DCF Advisers LLC now owns 751,579 shares of the company's stock valued at $2,510,000 after purchasing an additional 521,708 shares during the last quarter. Hedge funds and other institutional investors own 5.81% of the company's stock.

Evotec Stock Up 1.8%

EVO stock traded up $0.07 during midday trading on Friday, hitting $3.93. The company's stock had a trading volume of 57,832 shares, compared to its average volume of 76,105. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.93 and a current ratio of 2.03. Evotec AG has a 52-week low of $2.84 and a 52-week high of $5.64. The firm has a 50-day simple moving average of $4.08 and a 200-day simple moving average of $3.99.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Evotec from a "sell" rating to a "hold" rating in a report on Thursday, April 24th. Royal Bank Of Canada reiterated an "outperform" rating on shares of Evotec in a report on Thursday, May 15th.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.